Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14303510 | 1.00 | KCNH2 (0.91) | KCNH2HRH3 | |
| SCHEMBL14310563 | 0.96 | KCNH2 (0.93) | KCNH2HRH3 | |
| SCHEMBL3325230 | 0.96 | KCNH2 (0.98) | KCNH2HRH3 | |
| SCHEMBL3324977 | 0.96 | KCNH2 (0.93) | KCNH2HRH3 | |
| SCHEMBL14302691 | 0.96 | KCNH2 (0.98) | KCNH2HRH3 | |
| SCHEMBL14302692 | 0.95 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL3325296 | 0.95 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL14302697 | 0.92 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL14302704 | 0.92 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL14303861 | 0.92 | KCNH2 (0.88) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035372-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2008005338-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| EP-2807153-B1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-9708275-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2017-07-18 | — | — | US | disclosed |
| US-20160257656-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-09-08 | — | — | US | disclosed |
| US-20150011565-A1 | Heterocyclic Compounds and Methods For Their Use | NOVARTIS AG (CH) | 2015-01-08 | — | — | US | disclosed |
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2152669-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | Cephalon, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008137087-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | KCNH2 783/4885HRH3 1100/4885 |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | KCNH2 783/4885HRH3 1100/4885 |
| US-20160257656-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | AGTR2, AGTR1, BDKRB2 | KCNH2 450/4885HRH3 63/4885 |
| US-20150011565-A1 | Heterocyclic Compounds and Methods For Their Use | AGTR2, AGTR1, BDKRB2 | KCNH2 461/4885HRH3 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.